Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.86 |
| ▸ | EP300 | Q09472 | 3/20 | 0.83 |
| ▸ | CHAT | P28329 | 2/20 | 0.83 |
| ▸ | AURKA | O14965 | 2/20 | 0.83 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.83 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.83 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.72 |
| ▸ | NAA40 | Q86UY6 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14918771 | 0.97 | NAA50 (0.84) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL29806102 | 0.97 | NAA50 (0.84) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL21314167 | 0.97 | NAA50 (0.84) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL18925866 | 0.97 | NAA50 (0.84) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL18838134 | 0.96 | NAA50 (0.84) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL15018707 | 0.96 | NAA50 (0.85) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL28813886 | 0.96 | NAA50 (0.85) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL21874948 | 0.96 | NAA50 (0.85) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL416543 | 0.96 | NAA50 (0.85) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL12660840 | 0.96 | NAA50 (0.89) | NAA50EP300CHATAURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364629-A1 | MICROBIAL PRODUCTION OF 3,4-DIHYDROXYBUTYRATE (3,4-DHBA), 2,3- DIHYDROXYBUTYRATE (2,3-DHBA) AND 3-HYDROXYBUTYROLACTONE (3-HBL) | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-12-11 | — | — | US | disclosed |
| US-8669379-B2 | Microbial production of 3,4-dihydroxybutyrate (3,4-DHBA), 2,3-dihydroxybutyrate (2,3-DHBA) and 3-hydroxybutyrolactone (3-HBL) | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-03-11 | — | — | US | disclosed |
| US-20120226055-A1 | MICROBIAL PRODUCTION OF 3,4-DIHYDROXYBUTYRATE (3,4-DHBA), 2,3- DIHYDROXYBUTYRATE (2,3-DHBA) AND 3-HYDROXYBUTYROLACTONE (3-HBL) | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012116307-A1 | MICROBIAL PRODUCTION OF 3,4-DIHYDROXYBUTYRATE (3,4-DHBA), 2,3-DIHYDROXYBUTYRATE (2,3-DHBA) AND 3-HYDROXYBUTYROLACTONE (3-HBL) | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364629-A1 | MICROBIAL PRODUCTION OF 3,4-DIHYDROXYBUTYRATE (3,4-DHBA), 2,3- DIHYDROXYBUTYRATE (2,3-DHBA) AND 3-HYDROXYBUTYROLACTONE (3-HBL) | HSD17B10, HBB, HADHB | NAA50 1976/4885EP300 4452/4885CHAT 4397/4885 |
| US-20120226055-A1 | MICROBIAL PRODUCTION OF 3,4-DIHYDROXYBUTYRATE (3,4-DHBA), 2,3- DIHYDROXYBUTYRATE (2,3-DHBA) AND 3-HYDROXYBUTYROLACTONE (3-HBL) | HSD17B10, HBB, HADHB | NAA50 1976/4885EP300 4452/4885CHAT 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.